Wall Street Zen upgraded shares of Adlai Nortye (NASDAQ:ANL – Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday.
Several other research analysts have also weighed in on ANL. Oppenheimer began coverage on Adlai Nortye in a research report on Thursday, May 28th. They set an “outperform” rating and a $32.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a report on Tuesday, July 14th. JonesTrading initiated coverage on shares of Adlai Nortye in a research note on Thursday, May 14th. They issued a “buy” rating and a $22.00 target price for the company. Finally, Cantor Fitzgerald assumed coverage on shares of Adlai Nortye in a report on Monday, June 22nd. They set an “overweight” rating on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $24.25.
View Our Latest Stock Analysis on Adlai Nortye
Adlai Nortye Stock Down 0.1%
Hedge Funds Weigh In On Adlai Nortye
Institutional investors and hedge funds have recently modified their holdings of the stock. SmartHarvest Portfolios LLC lifted its stake in shares of Adlai Nortye by 8.5% during the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock worth $113,000 after buying an additional 1,279 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Adlai Nortye in the 1st quarter valued at about $457,000. Seven Fleet Capital Management LP acquired a new position in Adlai Nortye in the 2nd quarter valued at about $1,302,000. ADAR1 Capital Management LLC acquired a new position in Adlai Nortye in the 1st quarter valued at about $816,000. Finally, Affinity Asset Advisors LLC bought a new position in Adlai Nortye in the 1st quarter valued at about $1,140,000. 35.21% of the stock is currently owned by institutional investors and hedge funds.
Adlai Nortye Company Profile
Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.
Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.
The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.
Featured Stories
- Five stocks we like better than Adlai Nortye
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.
